Granted Patent
B2
US 12,721,833 · App. 17/912,477 · Granted Sep 1, 2026
Small molecule anticancer agents, combinations and uses thereof
Inventors:
Brian Keith Law (Gainesville, FL); Ronald K. Castellano (Gainesville, FL); Stephan Jahn (Gainesville, FL); Elham Yaaghubi (Gainesville, FL)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
Claims (46)
1 . A compound of Formula I, or salt thereof:
wherein,
(i) R 3 is halo or haloalkoxy; and R 4 is halo or haloalkoxy; or
(ii) R 3 is H or C 1 -C 6 alkoxy; and R 4 is halo or haloalkoxy; or
(iii) R 3 is halo or haloalkoxy; and R 4 is H or C 1 -C 6 alkoxy.
2 . The compound of claim 1 , or a salt thereof:
wherein,
R 3 is halo; and R 4 is halo; or
R 3 is halo; and R 4 is haloalkoxy.
3 . The compound of claim 1 , or a salt thereof:
wherein,
R 3 is haloalkoxy; and R 4 is haloalkoxy; or
R 3 is haloalkoxy; and R 4 is halo.
4 . The compound of claim 1 , or salt thereof:
wherein,
R 3 is H; and R 4 is halo; or
R 3 is H; and R 4 is haloalkoxy.
5 . The compound of claim 1 , or salt thereof:
wherein,
R 3 is C 1 -C 6 alkoxy; and R 4 is halo; or
R 3 is C 1 -C 6 alkoxy; and R 4 is haloalkoxy.
6 . The compound of claim 1 , or salt thereof:
wherein,
R 3 is halo or haloalkoxy; and R 4 is H; or
R 3 is halo or haloalkoxy; and R 4 is C 1 -C 6 alkoxy.
7 . The compound of claim 1 , or a salt thereof, according to:
(a) Formula (II):
or salt thereof;
(b) Formula (III):
or salt thereof; or
(c) any of Formula (IV-XI):
or salt thereof.
8 . The compound or a salt thereof of claim 1 , wherein the compound is of the formula:
or salt thereof.
9 . A pharmaceutical composition comprising a compound of claim 1 , or salt thereof, and a pharmaceutically acceptable carrier.
10 . The composition of claim 9 , further comprising an additional therapeutic agent.
11 . A method of inhibiting cell proliferation comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , or salt thereof, wherein the cell proliferation is modulated by HER2, HER3, and/or EGFR.
12 . The method of claim 11 , wherein the cell is a cancer cell.
13 . The method of claim 12 , wherein the cancer cell proliferation is modulated by HER2 mediated.
14 . The method of claim 12 , wherein the cancer cell is a breast cancer cell.
15 . The method of claim 14 , wherein the breast cancer cell is a HER2-positive breast cancer cell.
16 . The method of claim 14 , wherein the breast cancer cell proliferation is modulated by EGFR.
17 . A method of inhibiting cancer cell metastasis comprising administering to a subject in need thereof a therapeutically effective amount a compound of claim 1 , or a salt thereof, wherein the cancer cell metastasis is modulated by HER2, HER3, and/or EGFR.
18 . A method of treating cancer in a subject comprising administering to the subject a compound of claim 1 , or a salt thereof, wherein the cancer is modulated by HER2, HER3, and/or EGFR.
19 . The method of claim 18 , wherein the cancer is breast cancer, pancreatic cancer, prostate, oral, or non-small cell lung cancer (NSCLC).
20 . A kit for treating a cell proliferative disorder, the kit comprising a compound of claim 1 , or a salt thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 12, 2022
From: LAW, BRIAN KEITH; CASTELLANO, RONALD K.; JAHN, STEPHAN; YAAGHUBI, ELHAM
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 062053/0327 →
Continuity (3)
Provisional Application
63067651
· Aug 19, 2020
Provisional Application
62990544
· Mar 17, 2020
References Cited (115)
US 20120189543A1
· Wang et al.
· 2012
[cited by applicant]
US 20130273574A1
· Kidd et al.
· 2013
[cited by applicant]
US 20170240570A1
· Jahn et al.
· 2017
[cited by applicant]
US 20240118281A1
· Law et al.
· 2024
[cited by applicant]
WO WO2008104606A1
· 2008
[cited by applicant]
WO WO2011103091A1
· 2011
[cited by applicant]
WO WO2014048865A1
· 2014
[cited by applicant]
WO WO2018156600A1
· 2018
[cited by applicant]
WO WO2019241644A
· 2019
[cited by applicant]
WO WO2021188523A1
· 2021
[cited by applicant]
WO WO2022150754A1
· 2022
[cited by applicant]
Bass, Journal of Organic Chemistry, vol. 45, Issue 4, 1980, 710-715 (Year: 1980).
[cited by examiner]
Meanwell, Journal of Medicinal Chemistry, 2018, 61, 5822-5880 (Year: 2018).
[cited by examiner]
Jach, American Journal of Cancer Research, Nov. 15, 2021; 11 (11): 5249-5262 (Year: 2021).
[cited by examiner]
Schraps Cancer Medicine, 2024, 13: e70407 (Year: 2024).
[cited by examiner]
Meanwell, J. Med. Chem., 2018, 61, 5822-5880 (Year: 2018).
[cited by examiner]
Invitation to Pay Additional Fees for App. No. PCT/US2021/022542 mailed May 19, 2021.
[cited by applicant]
International Search Report and Written Opinion for App. No. PCT/US2021/022542 mailed Jul. 28, 2021.
[cited by applicant]
International Preliminary Report on Patentability for App. No. PCT/US2021/022542 mailed Sep. 29, 2022.
[cited by applicant]
Gray et al., Development of a fluorescent monoclonal antibody-based assay to measure the allosteric effects of synthetic peptides on self-oligomerization of AGR2 protein. Protein Sci. Sep. 2013;22(9):1266-78. doi: 10.10…
[cited by applicant]
Law et al., Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death. Cancer Lett. May 28, 2022;534:215604. doi: 10.1016/j.canlet.2022.215604. Epub …
[cited by applicant]
Anelli et al., Sequential steps and checkpoints in the early exocytic compartment during secretory IgM biogenesis. EMBO J. Oct. 3, 2007;26(19):4177-88. doi: 10.1038/sj.emboj.7601844. Epub Sep. 6, 2007.
[cited by applicant]
Arumugam et al., New Blocking Antibodies against Novel AGR2-C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice. Mol Cancer Ther. Apr. 2015;14(4):941-51. doi: 10.1158/1535-7163.…
[cited by applicant]
Ashkenazi et al., Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. Jul. 1999;104(2):155-62. doi: 10.1172/JCI6926.
[cited by applicant]
Barraclough et al., The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol. Nov. 2009;175(5):1848-57. doi: 10.2353/ajpath.2009.090246. Epub Oct. 15,…
[cited by applicant]
Bertoli et al., Two conserved cysteine triads in human Erolalpha cooperate for efficient disulfide bond formation in the endoplasmic reticulum. J Biol Chem. Jul. 16, 2004;279(29):30047-52. doi: 10.1074/jbc.M403192200. E…
[cited by applicant]
Besse et al., A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica. Sep. 2019;104(9):e415-e419. doi: 1…
[cited by applicant]
Bondi, van der Waals Volumes and Radii. J. Phys. Chem. 1964;68(3):441-51.
[cited by applicant]
Brychtova et al., Anterior gradient 2 and mucin 4 expression mirrors tumor cell differentiation in pancreatic adenocarcinomas, but aberrant anterior gradient 2 expression predicts worse patient outcome in poorly differe…
[cited by applicant]
Cha et al., Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem. Oct. 6, 2000;275(40):31171-7. doi: 10.1074/jbc.M004414200.
[cited by applicant]
Cho et al., Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. Dec. 15, 2011;71(24):7587-96. doi: 10.1158/…
[cited by applicant]
Corsino et al., A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism. J Biol Chem. Oct. 23, 2009;284(43):29945-55. doi: 10.1074/jbc.M109.055251. Epub Aug. 26…
[cited by applicant]
Cortini et al., ERp44 and ERGIC-53 synergize in coupling efficiency and fidelity of IgM polymerization and secretion. Traffic. May 2010;11(5):651-9. doi: 10.1111/j.1600-0854.2010.01043.x.
[cited by applicant]
Cortini et al., From antibodies to adiponectin: role of ERp44 in sizing and timing protein secretion. Diabetes Obes Metab. Oct. 2010;12 Suppl 2:39-47. doi: 10.1111/j.1463-1326.2010.01272.x.
[cited by applicant]
Costero et al., Crown ethers derived from cyclohexane. Influence of their stereohemistry in complexation and transport. Tetrahedron. 2002;58:6729-34.
[cited by applicant]
De Ruijter et al., Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. Feb. 2011;137(2):183-92. doi: 10.1007/s00432-010-0957-x. Epub Nov. 11, 2010.
[cited by applicant]
Derose et al., Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol. Mar. 2013;Chapter 14:Unit14.23. doi: 10.1…
[cited by applicant]
Derose et al., Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. Oct. 23, 2011;17(11):1514-20. doi: 10.1038/nm.2454. Author manus…
[cited by applicant]
Desantis et al., Breast cancer statistics, 2019. CA Cancer J Clin. Nov. 2019;69(6):438-451. doi: 10.3322/caac.21583. Epub Oct. 2, 2019.
[cited by applicant]
Di Maro et al., Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells. Mol Cancer. Jun. 30, 2014;13:160.
[cited by applicant]
Dong et al., Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface. J Biol Chem. Mar. 27,…
[cited by applicant]
Dumartin et al., ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Oncogene. Jun. 1, 2017;36(22):3094-3103. doi: 10.1038/onc.2016.459. Epub Dec. 12, 2016.
[cited by applicant]
Eriksson et al., Identification of PDI Substrates by Mechanism-Based Kinetic Trapping. Methods Mol Biol. 2019;1967:165-182. doi: 10.1007/978-1-4939-9187-7_10.
[cited by applicant]
Ferreira et al., Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Oncotarget. Apr. 25, 2017;8(17):28971-28989. doi: 10.18632/oncotarget.15952.
[cited by applicant]
Ferreira et al., Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Oncotarget. Apr. 30, 2015;6(12):10445-59. doi: 10.18632/oncotarget.3398.
[cited by applicant]
Fraldi et al., Multistep, sequential control of the trafficking and function of the multiple sulfatase deficiency gene product, SUMF1 by PDI, ERGIC-53 and ERp44. Hum Mol Genet. Sep. 1, 2008;17(17):2610-21. doi: 10.1093/…
[cited by applicant]
Frand et al., The ERO1 gene of yeast is required for oxidation of protein dithiols in the endoplasmic reticulum. Mol Cell. Jan. 1998;1(2):161-70. doi: 10.1016/s1097-2765(00)80017-9.
[cited by applicant]
Fritzsche et al., Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res. Mar. 15, 2006;12(6):1728-34. doi: 10.1158/1078-0432.CCR-05-2057.
[cited by applicant]
Galligan et al., The human protein disulfide isomerase gene family. Hum Genomics. Jul. 5, 2012;6(1):6. doi: 10.1186/1479-7364-6-6.
[cited by applicant]
Ghilardi et al., Anticancer Agents Derived from Cyclic Thiosulfonates: Structure-Reactivity and Structure-Activity Relationships. ChemMedChem. Jul. 19, 2022;17(14):e202200165. doi: 10.1002/cmdc.202200165. Epub May 23, 2…
[cited by applicant]
Ghilardi et al., Structure-reactivity studies involving thiosulfonate compounds capable of selectively killing HER2+ and EGFR+ breast cancer cells. American Chemical Society Fall 2020 Virtual Meeting. Aug. 2020. Poster …
[cited by applicant]
Gillis et al., Applications of Fluorine in Medicinal Chemistry. J Med Chem. Nov. 12, 2015;58(21):8315-59. doi: 10.1021/acs.jmedchem.5b00258. Epub Jul. 22, 2015.
[cited by applicant]
Guo et al., A humanized monoclonal antibody targeting secreted anterior gradient 2 effectively inhibits the xenograft tumor growth. Biochem Biophys Res Commun. Jun. 17, 2016;475(1):57-63. doi: 10.1016/j.bbrc.2016.05.033…
[cited by applicant]
Guo et al., Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Oncogene. Sep. 7, 2017;36(36):5098-5109. doi: 10.1038/onc.2017.132. Epub May 8, 20…
[cited by applicant]
Gupta et al., AGR2 gene function requires a unique endoplasmic reticulum localization motif. J Biol Chem. Feb. 10, 2012;287(7):4773-82. doi: 10.1074/jbc.M111.301531. Epub Dec. 19, 2011.
[cited by applicant]
Hampe et al., Regulation and Quality Control of Adiponectin Assembly by Endoplasmic Reticulum Chaperone ERp44. J Biol Chem. Jul. 17, 2015;290(29):18111-18123. doi: 10.1074/jbc.M115.663088. Epub Jun. 9, 2015.
[cited by applicant]
Hisatsune et al., ERp44 Exerts Redox-Dependent Control of Blood Pressure at the ER. Mol Cell. Jun. 18, 2015;58(6):1015-27. doi: 10.1016/j.molcel.2015.04.008. Epub May 7, 2015.
[cited by applicant]
Hu et al., Knockdown of AGR2 induces cellular senescence in prostate cancer cells. Carcinogenesis. Jun. 2012;33(6):1178-86. doi: 10.1093/carcin/bgs141. Epub Mar. 31, 2012.
[cited by applicant]
Innes et al., Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer. Apr. 10, 2006;94(7):1057-65. doi: 10.1038/sj.bjc.6603065.
[cited by applicant]
Jia et al., Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-κB pathway. Biochim Biophys Acta Mol Basis Dis. May 2018;1864(5 Pt…
[cited by applicant]
Keller et al., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. Oct. 15, 2002;74(20):5383-92. doi: 10.1021/ac025747h.
[cited by applicant]
Koller et al., Zinc-mediated formation of trifluoromethyl ethers from alcohols and hypervalent iodine trifluoromethylation reagents. Angew Chem Int Ed Engl. 2009;48(24):4332-6.
[cited by applicant]
Kubyshkin et al., Amide rotation trajectories probed by symmetry. Organic & Biomolecular Chemistry. Jul. 2017;15(32):6764-72.
[cited by applicant]
Kubyshkin et al., Energetic contribution to both acidity and conformational stability in peptide models. New Journal of Chemisty. Mar. 2016;40(6):5209-20.
[cited by applicant]
Laboissiere et al., The essential function of protein-disulfide isomerase is to unscramble non-native disulfide bonds. J Biol Chem. Nov. 24, 1995;270(47):28006-9. doi: 10.1074/jbc.270.47.28006.
[cited by applicant]
Lacambra et al., Anterior Gradient 2 is a Poor Outcome Indicator in Luminal Breast Cancer. Ann Surg Oncol. Oct. 2015;22(11):3489-96. doi: 10.1245/s10434-015-4420-8. Epub Feb. 7, 2015.
[cited by applicant]
Law et al., CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Res. Aug. 5, 2016;18(1):80. doi: 10.1186/s13058-016-0741-1.
[cited by applicant]
Law et al., Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. J Biol Chem. Apr. 14, 2000;275(15):10796-801. doi: 10.1074/jbc.275.15.10796.
[cited by applicant]
Law et al., Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene. Mar. 7, 2013;32(10):1316-29. doi: 10.1038/onc.2012…
[cited by applicant]
Law et al., Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol. Dec. 2002;22(23):8184-98. doi: 10.1128/MCB.22.23.81…
[cited by applicant]
Law et al., Repurposing Tranexamic Acid as an Anticancer Agent. bioRxiv. Oct. 17, 2021; doi: 10.1101/2021.10.17.464714. https://www.biorxiv.org/content/10.1101/2021.10.17.464714v1, 27 pages.
[cited by applicant]
Law et al., Repurposing Tranexamic Acid as an Anticancer Agent. Front Pharmacol. Jan. 13, 2022;12:792600.
[cited by applicant]
Law et al., Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J Biol Chem. Dec. 8, 2000;275(49):38261-7. …
[cited by applicant]
Lemmon et al., Cell signaling by receptor tyrosine kinases. Cell. Jun. 25, 2010;141(7):1117-34. doi: 10.1016/j.cell.2010.06.011.
[cited by applicant]
Liu et al., AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. Oncotarget. Jul. 2, 2019;10(42):4276-4289. doi: 10.18632/oncotarget.26945.
[cited by applicant]
Liu et al., EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. Jun. 2012;29(2):401-5. doi: 10.1007/s12032-…
[cited by applicant]
Liu et al., Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res. May 1, 2005;65(9):3796-805.
[cited by applicant]
Liu et al., Silver-Mediated Oxidative Trifluoromethylation of Alcohols to Alkyl Trifluoromethyl Ethers. Org Lett. Oct. 16, 2015;17(20):5048-51. doi: 10.1021/acs.orglett.5b02522. Epub Sep. 29, 2015.
[cited by applicant]
Long et al., Peroxisome proliferator-activated receptor-gamma increases adiponectin secretion via transcriptional repression of endoplasmic reticulum chaperone protein ERp44. Endocrinology. Jul. 2010;151(7):3195-203. do…
[cited by applicant]
Narumi et al., Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues. Int J Biol Markers. May 26, 2015;30(2):e234-42. doi: 10.5301/jbm.5000131.
[cited by applicant]
Negi et al., Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study. Cancer Lett. May 1, 2019;4…
[cited by applicant]
Nesvizhskii et al., A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. Sep. 1, 2003;75(17):4646-58. doi: 10.1021/ac0341261.
[cited by applicant]
Otsu et al., Dynamic retention of Erolalpha and Erolbeta in the endoplasmic reticulum by interactions with PDI and ERp44. Antioxid Redox Signal. Mar.-Apr. 2006;8(3-4):274-82. doi: 10.1089/ars.2006.8.274.
[cited by applicant]
Pan et al., Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling. Cell. Mar. 7, 2019;176(6): 1477-1489.e14. doi: 10.1016/j.cell.2019.02.001. Epub Feb. 28, 2019.
[cited by applicant]
Park et al., Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol. 2001;41:443-70. doi: 10.1146/annurev.pharmtox.41.1.443.
[cited by applicant]
Park et al., The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci U S A. Apr. 28, 2009;106(17):6950-5. doi: 10.1073/pnas.0808722106. Epub Apr. 9, 2009.
[cited by applicant]
Pollard et al., Ero1p: a novel and ubiquitous protein with an essential role in oxidative protein folding in the endoplasmic reticulum. Mol Cell. Jan. 1998;1(2):171-82. doi: 10.1016/s1097-2765(00)80018-0.
[cited by applicant]
Rieger et al., APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. May 1, 1998;427(1):124-8. doi: 10.1016/s0014-5793(98)00409-8.
[cited by applicant]
Rodriguez Sarmiento et al., Chemoenzymatic preparation of non-racemic N-Boc-pyrrolidine-3,4-dicarboxylic acid 3-ethyl esters and their 4-hydroxymethyl derivatives. Tetrahedron: Asymmetry. Jun. 6, 2003;14(11):1547-51.
[cited by applicant]
Sannino et al., Progressive quality control of secretory proteins in the early secretory compartment by ERp44. J Cell Sci. Oct. 1, 2014;127(Pt 19):4260-9. doi: 10.1242/jcs.153239. Epub Aug. 5, 2014.
[cited by applicant]
Schroeder et al., AGR2 is induced in asthma and promotes allergen-induced mucin overproduction. Am J Respir Cell Mol Biol. Aug. 2012;47(2):178-85. doi: 10.1165/rcmb.2011-0421OC. Epub Mar. 8, 2012.
[cited by applicant]
Shergalis et al., Role of the ERO1-PDI interaction in oxidative protein folding and disease. Pharmacol Ther. Jun. 2020;210:107525. doi: 10.1016/j.pharmthera.2020.107525. Epub Mar. 20, 2020. Author manuscript, 40 pages.
[cited by applicant]
Stockhausen et al., Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res. Jul. 1, 2011;317(11):1513-26. doi: 10.1016/j.yexcr.2011.04.001. Epub Apr.…
[cited by applicant]
Stojak et al., Protein Disulphide Isomerase A1 Is Involved in the Regulation of Breast Cancer Cell Adhesion and Transmigration via Lung Microvascular Endothelial Cells. Cancers (Basel). Oct. 2, 2020;12(10):2850. doi: 10…
[cited by applicant]
Stopa et al., Kinetic-based trapping by intervening sequence variants of the active sites of protein-disulfide isomerase identifies platelet protein substrates. J Biol Chem. Jun. 2, 2017;292(22):9063-9074. doi: 10.1074/…
[cited by applicant]
Tempio et al., The pivotal role of ERp44 in patrolling protein secretion. J Cell Sci. Nov. 10, 2020;133(21):jcs240366. doi: 10.1242/jcs.240366.
[cited by applicant]
Thapa et al., TRAIL therapy and prospective developments for cancer treatment. J Control Release. Oct. 10, 2020;326:335-349. doi: 10.1016/j.jconrel.2020.07.013. Epub Jul. 17, 2020.
[cited by applicant]
Tomoshige et al., An EGFTOMR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo. Oncogene. Jul. 2018;37(28):3894-3908. doi: 10.1038/s41388-018-0240-1. Epub Apr. 17, 2018.
[cited by applicant]
Toyama et al., Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer. Oct. 25, 2008;8:309. doi: 10.1186/1471…
[cited by applicant]
Wang et al., A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Oncogene. May 2019;38(22):4264-4282. doi: 10.1038/s41388-019-0717-6. Epub Feb. 4, 2019.
[cited by applicant]
Wang et al., Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Cell Death Discov. Dec. 10, 2019;5:153. doi: 10.1038/s41420-019-0228-9.
[cited by applicant]
Wang et al., Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011). Chem Rev. Feb. 26, 2014;114(4):2432-506. doi: 10.1021/cr4002879. Epub Dec. 3, 2013.
[cited by applicant]
Wang et al., Mechanistic Elucidation of the Antitumor Properties of a Novel Death Receptor 5 Activator. bioRxiv. Jul. 14, 2019. doi: https://doi.org/10.1101/700906.
[cited by applicant]
Wang et al., Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol. May 2007;27(10):3716-31. doi: 10.1128/MCB.00931-06. Epub Mar. 12, 200…
[cited by applicant]
Wang et al., The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. Jan. 15, 2008;68(2):492-7. doi: 10.1158/0008-5472.CAN-07-2930.
[cited by applicant]
Wiley et al., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. Dec. 1995;3(6):673-82. doi: 10.1016/1074-7613(95)90057-8.
[cited by applicant]
Wolf, New insights into thiol-mediated regulation of adiponectin secretion. Nutr Rev. Nov. 2008;66(11):642-5. doi: 10.1111/j.1753-4887.2008.00115.x.
[cited by applicant]
Xu et al., Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. Theranostics. Apr. 12, 2019;9(8):2282-2298. doi: 10.7150/thno.30621.
[cited by applicant]
Yaaghubi, Cyclic Thiosulfonates (DDAS) as Novel Anticancer Therapeutics against EGFR+ and HER2+ Tumors. University of Florida Dissertation. Jan. 2021.
[cited by applicant]
Yaaghubi, Optimizing cyclic thiosulfonates, DDAs, as potent anticancer agents against HER2+ and EGFR+ breast cancer cells. American Chemical Society Fall 2020 Virtual Meeting. Aug. 2020. Presentation and Abstract.
[cited by applicant]
Yang et al., Crystal Structure of the ERp44-Peroxiredoxin 4 Complex Reveals the Molecular Mechanisms of Thiol-Mediated Protein Retention. Structure. Oct. 4, 2016;24(10):1755-1765. doi: 10.1016/j.str.2016.08.002. Epub Se…
[cited by applicant]
Zamai et al., Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. Dec. 21, 1998;188(12):2375-80. doi: 10.1084/jem.188.12.237…
[cited by applicant]
Zhang et al., AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer. Jul. 2005;43(3):249-59. doi: 10.1002/gcc.20188.
[cited by applicant]